Context.-Metastatic metaplastic breast carcinoma (MPBC) is an uncommon, but aggressive, tumor resistant to conventional chemotherapy.
M
etaplastic carcinoma of the breast (MPBC) is an uncommon, malignant tumor with a variable histologic appearance that differs substantially from classic invasive ductal adenocarcinoma and invasive lobular adenocarcinoma. [1] [2] [3] [4] [5] Metaplastic carcinoma of the breast typically presents at a more-advanced stage than either invasive ductal or lobular adenocarcinoma cases and, in general, has a worse prognosis. 6, 7 On routine biomarker testing for estrogen receptor (ER) and/or progesterone receptor (PR) status, most MPBCs are negative. 8 Similarly, virtually all MPBC cases are negative for HER2 overexpression and amplification by either immunohistochemistry (IHC) and/or fluorescence in situ hybridization. 8, 9 These findings combined with messenger RNA (mRNA) profiling studies indicate that most MPBCs are so-called triple-negative breast cancers (TNBCs) that cluster with the basaloidphenotype cancers in the breast cancer molecular-portraits system. [10] [11] [12] However, although the TNBC and basaloid types of breast cancer are classically associated with responsiveness to cytotoxic chemotherapy, 13, 14 metastatic MPBC is generally regarded as a chemoresistant, highly aggressive form of the disease. 15, 16 Given the poor prognosis and reduced response to treatment for MPBC, this study was performed to evaluate potential, targeted treatment opportunities for patients with MPBC. 
MATERIALS AND METHODS
Hybridization capture of 3769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to a minimum of 50 ng of DNA extracted from 20 formalin-fixed, paraffin-embedded cases of relapsed and metastatic MPBC that had previously been treated with systemic therapies. 17 There were no early stage or untreated MPBC cases included in this study. The 20 cases represented all (100%) of the MPBC samples received at Foundation Medicine, Inc (Cambridge, Massachusetts), for next-generation sequencing between January 1, 2013, and February 1, 2014. The 20 MPBC samples were sequenced to high, uniform coverage (average 3833, with .99% of exons covered at greater than 3100). All MPBC cases were reviewed by 2 pathologists (J.S.R. and S.B.) and were subdivided into histologic subtypes: predominantly spindle cell (sarcomatoid), predominantly squamous, predominantly chondroid, and mixed. Formalin-fixed, paraffin-embedded specimens were sequenced to high (average 3833), uniform coverage, as previously described. 17 Genomic alterations (base substitutions, small insertions/deletions [indels], select rearrangements, and copy-number alterations) were determined. Potentially actionable alterations were defined as those linked to anticancer drugs on the market or in registered clinical trials. Local site permissions to use clinical samples and their accompanying medical records and pathology reports were used for this study. No additional research was performed on the tumor samples beyond the DNA sequencing.
RESULTS
The 20 patients with MPBC had a median age of 62 years (range, 42-86 years). There were 9 predominantly squamous (45%), 9 predominantly chondroid (45%), and 2 predominantly spindle cell (sarcomatoid) (10%) MPBCs, all of which were originally diagnosed as high-grade tumors (Table 1 ). All MPBCs (20 of 20; 100%) had pure MPBC histology, and none of the cases (0 of 20; 0%) in this series had foci of either classic invasive ductal carcinoma or invasive lobular carcinoma admixed with the metaplastic carcinoma areas. All of the MPBCs (20 of 20; 100%) were advanced stage: 1 MPBC (5%) was stage II, 2 (10%) were stage III, and 17 (85%) were stage IV. Because this study included only patients with relapsed and metastatic disease, there were no well-differentiated or stage-I tumors included in this patient cohort. Of the 16 cases (80%) with available biomarker results, 6% (n ¼ 1) were ER The most-common, biologically relevant alterations were alterations in TP53 (n ¼ 15; 75%), MYC (n ¼ 6; 30%), MLL2 (n ¼ 6; 30%), and KDM6A (n ¼ 2; 10%). The most-common, potentially targetable alterations were mutations, amplifications, and homozygous deletions of PIK3CA (n ¼ 8; 40%), PTEN (n ¼ 5; 25%), CDKN2A/B (n ¼ 4; 20%), CCND3 (n ¼ 3; 15%), CCNE1 (n ¼ 2; 10%), and EGFR (n ¼ 2; 10%), with AKT3, CCND1, CCND2, CDK4, FBXW7, FGFR1, HRAS, NF1, PIK3R1, and SRC altered in a single case (Figure 1 ; Table 1 ). The actionable alterations discovered in the MPBC have potential for a variety of targeted therapies, including inhibitors of mTOR, cyclin-dependent kinase inhibitors, MEK, EGFR, FGFR1, and SRC. The results of routine HER2 testing were available for 16 patients (80%) with MPBC and all (100%) were negative for HER2 overexpression, as determined by IHC and/or negative for HER2 amplification as determined by fluorescence in situ hybridization at outside laboratories. All 16 (100%) of those cases were also negative for ERBB2 copy-number gain (amplification) by the next-generation sequencing assay.
COMMENT Molecular studies of MPBC to date have predominantly used IHC, fluorescence in situ hybridization, and mRNA transcriptional profiling techniques and have demonstrated that MPBC clusters with the TNBC/basaloid phenotypes. [20] [21] [22] Metaplastic carcinomas of the breast have further been associated with the so-called claudin-low subtype of the basaloid phenotype in the molecular-portraits system. 23 In addition, mRNA profiling has linked the various histologic appearances of MPBC to various expression of a diverse group of genes. [24] [25] Studies 26 of TP53 have demonstrated that TP53 mutation is present in both the epithelial and mesenchymal components in MPBC with mixed histologies at a similar frequency (~75%). In the current study, the 20 MPBCs showed a histologically uniform pattern in that none of the tumors featured a mixture of differentiated invasive ductal adenocarcinoma with metaplastic spindle cell (sarcomatoid), squamous, or chondroid foci. Although the numbers of cases in each category is small, we identified no specific pattern of altered cancer genes that were associated with the sarcomatoid (spindle cell), squamous, or chondroid histologic subtypes. Similarly, when the MPBC cases are categorized into pure epithelial (0 cases; 0%), pure mesenchymal (7 cases; 35%), and mixed epithelial and mesenchymal (13 cases; 65%) groups, no significant differences in the genomic alterations between groups was observed. Instead, similar to prior profiling studies, we identified a heterogeneous combination of alterations, yielding a relatively unique mutation profile for each tumor despite apparent histologic similarities. Additionally, the current study also confirms 2 noteworthy findings from previously published MPBC transcriptional profiling studies: EGFR amplification in the absence of EGFR mutations [27] [28] and alterations in the Wnt signaling pathway without mutations in CTNNB1. [29] [30] [31] Given the histologic picture of MPBC with various types of mesenchymal differentiation, including the spindle cell (sarcomatoid) and chondroid variants of the disease, there has been significant interest in studying genes and biologic pathways associated with the epithelial to mesenchymal transition and the cancer stem cell hypothesis [32] [33] [34] [35] [36] [37] in MPBC. Previous studies using IHC or mRNA profiling of MPBC have identified altered expression levels of epithelial to mesenchymal transition genes or directly related pathways. In particular, altered expression of SNAIL, a transcriptional repressor of E-cadherin (CDH1), has been proposed as an important epithelial-mesenchymal transition pathway gene associated with recurrence and metastasis in the disease, especially in the chondroid variant of MPBC. [38] [39] [40] However, in this study, sequence alterations or copy-number gains or losses of these epithelial-mesenchymal transition-associated genes were not identified. In particular, no mutations or homozygous deletions of CDH1 were identified in this study.
The disease-free and overall survival results for patients with MPBC is significantly shorter than that for non-MPBC treated with cytotoxic agents in either the metastatic or the neoadjuvant settings. [12] [13] [14] Nineteen of the 20 MPBC cases (95%) in this series harbored 36 alterations that could potentially lead to a targeted, therapeutic treatment option (mean [SD], 1.8 [1.06] per tumor). This result is similar to a series 41 of 273 routine (non-MPBC) breast cancers evaluated using the same assay, where 246 (90%) harbored at least one potentially actionable alteration. The clinically meaningful alterations that could conceivably guide targeted treatment decisions were identified in 19 of 20 (95%) of the patients in multiple, biologic pathways (Table 2) . Cell-cycle alterations were common, including homozygous deletion of CDKN2A in 4 (20%) and amplifications of CCND3, CCNE1, CCND1, CCND2, and CDK4 in 8 (40%) of the MPBC cases, a subset of which may indicate the potential for use of cell-cycle inhibitors. An example is case B07, a chest wall relapse of a MPBC in a 61-year-old woman whose tumor demonstrated amplification of CDK4 (17 copies), in addition to amplification of MYC (9 copies) and the R248Q base substitution in TP53 (Figure 2 , A through C). CDK4 amplification has been reported 42 in 1.5% to 15% of breast carcinomas and expression has been correlated with amplification. Recent results [43] [44] [45] [46] focused on targeting cell-cycle regulatory genes in clinical trials for patients with cancer, and alterations in those cell growth regulatory pathways are showing significant promise.
PIK3CA mutations are important genomic alterations in the pathogenesis and progression of breast cancer. [47] [48] [49] PIK3CA mutations were identified in 8 (40%) of the patients with MPBC in the current study ( Figure 3, A and B) , which is consistent with a previous study 35 that demonstrated PIK3CA mutations in 9 of 19 MPBCs (48%). The PIK3CA mutation frequency in MPBC thus appears to be greater than the 25% frequency listed for all types of breast cancer 50 and for TNBCs as a group. 51 PIK3CA mutations have been linked to improved outcomes in breast cancer. 52 The PI3K pathway is now widely considered a target of therapy for cancer in general 53 and for breast cancer, in particular. 54 Moreover, activating mutations in PIK3CA predict sensitivity to inhibitors of PI3K or its downstream signaling pathway (the PI3K/AKT/mTOR pathway). 55 The mTOR inhibitor everolimus has been approved for use in hormone receptor-positive, HER2 À , advanced breast cancer, in combination with exemestane, and clinical trials with other mTOR inhibitors continue in breast cancer.
56 PTEN (phos- 50 in 5% of breast cancers but have not been previously analyzed, to our knowledge, specifically in metaplastic breast carcinoma. In this study, 5 of the 20 MPBC cases (25%) harbored PTEN alterations, including 3 homozygous deletions and 2 truncating mutations, which could potentially benefit from PI3K inhibitors in at least a subset of these typically difficultto-treat breast cancers.
In summary, MPBC is a rare, aggressive subtype of breast cancer, which remains a significant clinical problem given the high propensity to present at advanced stages and progress rapidly in a chemoresistant fashion. This study identified at least one clinically meaningful alteration that could potentially lead to a targeted treatment option in most patients. However, the future effect of the cost of the nextgeneration sequencing testing and potential use of targeting agents for metastatic MPBC must be weighed against the potential for increasing disease-free and overall survival in this disease. Moreover, the further development of personalized oncology for MPBC and all types of breast cancer will require the continued development of mechanisms driven clinical trials, such as the emerging umbrella and basket trials, which are based on the use of biomarkers to select patients for both single-agent and multiagent, novel treatments. Given the poor prognosis and limited treatment options for patients with metastatic MPBC, genomic profiling using next-generation sequencing has the potential to identify new treatment paradigms and to fulfill an unmet clinical need in this disease. 
